<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34756160</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>18</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>12</Issue><PubDate><Year>2021</Year><Month>Dec</Month><Day>02</Day></PubDate></JournalIssue><Title>Human vaccines &amp; immunotherapeutics</Title><ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation></Journal><ArticleTitle>Evaluation of the cross-neutralization activities elicited by Coxsackievirus A10 vaccine strains.</ArticleTitle><Pagination><StartPage>5334</StartPage><EndPage>5347</EndPage><MedlinePgn>5334-5347</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2021.1978792</ELocationID><Abstract><AbstractText>Increased severity of diseases caused by Coxsackievirus A10 (CV-A10) as well as a large number of mutants and recombinants circulating in the population are a cause of concern for public health. A vaccine with broad-spectrum and homogenous protective capacity is needed to prevent outbreaks of CV-A10. Here, we evaluated cross-neutralization of prototype strain and 17 CV-A10 strains from related manufacturers in mainland China <i>in vitro</i> using 30 samples of plasma collected from naturally infected human adults and 18 sera samples from murine immunized with the above strains of CV-A10. Both human plasma and murine sera exhibited varying degrees of cross-neutralizing activities. Prototype A/Kowalik and sub-genotype C3/S113 were most difficult to neutralize. Among all strains tested, neutralization of S102 and S108 strains by 18 different sera was the most uniform, suggesting their suitability for detection of NtAb titers of different vaccines for avoiding biases introduced by detection strain. Furthermore, among all immune-sera, cross-neutralization of the 18 strains of CV-A10 by anti-S110 and anti-S102 was the most homogenous. Anti-S102 exhibiting higher geometric mean titer (GMT) <i>in vitro</i> was evaluated for its cross-protection capacity <i>in vivo</i>. Remarkably, administration of anti-S102 protected mice from lethal dosage of eight strains of CV-A10. These results provide a framework for formulating strategies for the R&amp;D of vaccines targeting CV-A10 infections.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huo</LastName><ForeName>Yaqian</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Hepatitis Virus and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Research &amp; Development, Shanghai Institute of Biological Products Co., Ltd, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Jinghuan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Hepatitis Virus and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Pei</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Division of Hepatitis Virus and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Bopei</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of Hepatitis Virus and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Chenfei</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Hepatitis Virus and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Siyuan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Hepatitis Virus and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Fangyu</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Research &amp; Development, Taibang Biologic Group, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Xujia</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Division of Hepatitis Virus and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bian</LastName><ForeName>Lianlian</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Hepatitis Virus and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Fan</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Division of Hepatitis Virus and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Xing</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Division of Hepatitis Virus and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Jiuyue</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medical &amp; Scientific Affairs, Taibang Biologic Group, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Tong</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-1638-6214</Identifier><AffiliationInfo><Affiliation>State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Sciences, Xiamen University, Xiamen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiuling</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Research &amp; Development, Shanghai Institute of Biological Products Co., Ltd, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Qunying</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Division of Hepatitis Virus and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Zhenglun</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Division of Hepatitis Virus and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Vaccin Immunother</MedlineTA><NlmUniqueID>101572652</NlmUniqueID><ISSNLinking>2164-5515</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D044482">Benzeneacetamides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010881">Piperidones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>16VY3TM7ZO</RegistryNumber><NameOfSubstance UI="C052091">antineoplaston A10</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044482" MajorTopicYN="N">Benzeneacetamides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="Y">Enterovirus A, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="Y">Hand, Foot and Mouth Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010881" MajorTopicYN="Y">Piperidones</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Coxsackievirus A10</Keyword><Keyword MajorTopicYN="N">cross-neutralization</Keyword><Keyword MajorTopicYN="N">cross-protection</Keyword><Keyword MajorTopicYN="N">hand, foot, and mouth disease (HFMD)</Keyword><Keyword MajorTopicYN="N">vaccine candidate</Keyword></KeywordList><CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>10</Day><Hour>13</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>11</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34756160</ArticleId><ArticleId IdType="pmc">PMC8903991</ArticleId><ArticleId IdType="doi">10.1080/21645515.2021.1978792</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Oberste MS, Penaranda S, Maher K, Pallansch MA.. Complete genome sequences of all members of the species Human enterovirus A. J Gen Virol. 2004;85:1597&#x2013;607. doi:10.1099/vir.0.79789-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.79789-0</ArticleId><ArticleId IdType="pubmed">15166444</ArticleId></ArticleIdList></Reference><Reference><Citation>Itagaki A, Ishihara J, Mochida K, Ito Y, Saito K, Nishino Y, Koike S, Kurimura T. A clustering outbreak of hand, foot, and mouth disease caused by Coxsackie virus A10. Microbiol Immunol. 1983;27(11):929&#x2013;35. doi:10.1111/j.1348-0421.1983.tb 00658.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1348-0421</ArticleId><ArticleId IdType="pubmed">6321911</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y, Yeo A, Phoon MC, Tan EL, Poh CL, Quak SH, Chow VTK. The largest outbreak of hand; foot and mouth disease in Singapore in 2008: the role of enterovirus 71 and coxsackievirus A strains. Int J Infect Dis. 2010;14(12):e1076&#x2013;81. doi:10.1016/j.ijid.2010.07.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2010.07.006</ArticleId><ArticleId IdType="pubmed">20952237</ArticleId></ArticleIdList></Reference><Reference><Citation>Blomqvist S, Klemola P, Kaijalainen S, Paananen A, Simonen M-L, Vuorinen T, Roivainen M. Co-circulation of coxsackieviruses A6 and A10 in hand, foot and mouth disease outbreak in Finland. J Clin Virology. 2010;48(1):49&#x2013;54. doi:10.1016/j.jcv.2010.02.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2010.02.002</ArticleId><ArticleId IdType="pubmed">20189452</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirand A, Henquell C, Archimbaud C, Ughetto S, Antona D, Bailly JL, Peigue-Lafeuille H. Outbreak of hand, foot and mouth disease/herpangina associated with coxsackievirus A6 and A10 infections in 2010, France: a large citywide, prospective observational study. Clin Microbiol Infect. 2012. May;18(5):E110&#x2013;8. doi:10.1111/j.1469-0691.2012.03789.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1469-0691.2012.03789.x</ArticleId><ArticleId IdType="pubmed">22404077</ArticleId></ArticleIdList></Reference><Reference><Citation>Tseng FC, Huang HC, Chi CY, Lin TL, Liu CC, Jian JW, Hsu L-C, Wu H-S, Yang J-Y, Chang Y-W, et al. Epidemiological survey of enterovirus infections occurring in Taiwan between 2000 and 2005: analysis of sentinel physician surveillance data. J Med Virol. 2007;79:1850&#x2013;60. doi:10.1002/jmv.21006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.21006</ArticleId><ArticleId IdType="pubmed">17935170</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo SH, Huang YC, Huang CG, Tsao KC, Li WC, Hsieh YC, Chiu C-H, Lin T-Y. Clinical and epidemiologic features of Coxsackievirus A6 infection in children in northern Taiwan between 2004 and 2009. J Microbiol Immunol Infect. 2011;44:252&#x2013;57. doi:10.1016/j.jmii.2011.01.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmii.2011.01.031</ArticleId><ArticleId IdType="pubmed">21524960</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoang MTV, Nguyen TA, Tran TT, Vu TTH, Le NTN, Nguyen THN, Le THN, Nguyen TTH, Nguyen TH, Le NTN, et al. Clinical and aetiological study of hand, foot and mouth disease in southern Vietnam, 2013&#x2013;2015: inpatients and outpatients. Int J Infect Dis. 2019;80:1&#x2013;9. doi:10.1016/j.ijid.2018.12.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2018.12.004</ArticleId><ArticleId IdType="pmc">PMC6403263</ArticleId><ArticleId IdType="pubmed">30550944</ArticleId></ArticleIdList></Reference><Reference><Citation>Nhan LNT, Khanh TH, Hong NTT, Van HMT, Nhu LNT, Ny NTH, Nguyet LA, Thanh TT, Anh NT, Hang VTT, et al. Clinical, etiological and epidemiological investigations of hand, foot and mouth disease in southern Vietnam during 2015-2018. PLoS Negl Trop Dis. 2020;14:e0008544. doi:10.1371/journal.pntd.0008544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0008544</ArticleId><ArticleId IdType="pmc">PMC7451980</ArticleId><ArticleId IdType="pubmed">32804980</ArticleId></ArticleIdList></Reference><Reference><Citation>Nhan LNT, Turner HC, Khanh TH, Hung NT, Lien LB, Hong NTT, Nhu LNT, Ny NTH, Nguyet LA, Thanh TT, et al. Economic burden attributed to children presenting to hospitals with hand, foot, and mouth disease in Vietnam. Open Forum Infect Dis. 2019;6. doi:10.1093/ofid/ofz284</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofz284</ArticleId><ArticleId IdType="pmc">PMC6657964</ArticleId><ArticleId IdType="pubmed">31363772</ArticleId></ArticleIdList></Reference><Reference><Citation>Witso E, Palacios G, Cinek O, Stene LC, Grinde B, Janowitz D, Lipkin WI, R&#xf8;nningen KS. High prevalence of human enterovirus a infections in natural circulation of human enteroviruses. J Clin Microbiol. 2006;44(11):4095&#x2013;100. doi:10.1128/JCM.00653-06.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.00653-06</ArticleId><ArticleId IdType="pmc">PMC1698346</ArticleId><ArticleId IdType="pubmed">16943351</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatproedprai S, Theanboonlers A, Korkong S, Thongmee C, Wananukul S, Poovorawan Y. Clinical and molecular characterization of hand-foot-and-mouth disease in Thailand, 2008-2009. Jpn J Infect Dis. 2010 Jul;63(4):229&#x2013;33</Citation><ArticleIdList><ArticleId IdType="pubmed">20657060</ArticleId></ArticleIdList></Reference><Reference><Citation>Linsuwanon P, Puenpa J, Huang SW, Wang YF, Mauleekoonphairoj J, Wang JR, Poovorawan Y. Epidemiology and seroepidemiology of human enterovirus 71 among Thai populations. J Biomed Sci. 2014. Feb 18;21(1):16. doi:10.1186/1423-0127-21-16</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1423-0127-21-16</ArticleId><ArticleId IdType="pmc">PMC3937078</ArticleId><ArticleId IdType="pubmed">24548776</ArticleId></ArticleIdList></Reference><Reference><Citation>Puenpa J, Mauleekoonphairoj J, Linsuwanon P, Suwannakarn K, Chieochansin T, Korkong S, Theamboonlers A, Poovorawan Y. Prevalence and characterization of enterovirus infections among pediatric patients with hand foot mouth disease, herpangina and influenza like illness in Thailand, 2012. PLoS One. 2014. Jun 2;9(6):e98888. doi:10.1371/journal.pone.0098888</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0098888</ArticleId><ArticleId IdType="pmc">PMC4041783</ArticleId><ArticleId IdType="pubmed">24887237</ArticleId></ArticleIdList></Reference><Reference><Citation>Gopalkrishna V, Patil PR, Patil GP, Chitambar SD. Circulation of multiple enterovirus serotypes causing hand, foot and mouth disease in India. J Med Microbiol. 2012;61:420&#x2013;25. doi:10.1099/jmm.0.036400-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/jmm.0.036400-0</ArticleId><ArticleId IdType="pubmed">22052995</ArticleId></ArticleIdList></Reference><Reference><Citation>Davia JL, Bel PH, Ninet VZ, Bracho MA, Gonzalez-Candelas F, Salazar A, Gobernado M, Bosch IF. Onychomadesis outbreak in Valencia, Spain associated with hand, foot, and mouth disease caused by enteroviruses. Pediatr Dermatol. 2011;28:1&#x2013;5. doi:10.1111/j.1525-1470.2010.01161.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1525-1470.2010.01161.x</ArticleId><ArticleId IdType="pubmed">20553401</ArticleId></ArticleIdList></Reference><Reference><Citation>He YQ, Chen L, Xu WB, Yang H, Wang HZ, Zong WP, Xian H-X, Chen H-L, Yao X-J, Hu Z-L, et al. Emergence, circulation, and spatiotemporal phylogenetic analysis of coxsackievirus a6- and coxsackievirus a10-associated hand, foot, and mouth disease infections from 2008 to 2012 in Shenzhen, China. J Clin Microbiol. 2013;51:3560&#x2013;66. doi:10.1128/JCM.01231-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.01231-13</ArticleId><ArticleId IdType="pmc">PMC3889734</ArticleId><ArticleId IdType="pubmed">23966496</ArticleId></ArticleIdList></Reference><Reference><Citation>He SZ, Chen MY, Xu XR, Yan Q, Niu JJ, Wu WH, Su XS, Ge SX, Zhang SY, Xia NS, et al. Epidemics and aetiology of hand, foot and mouth disease in Xiamen, China, from 2008 to 2015. Epidemiol Infect. 2017;145:1865&#x2013;74. doi:10.1017/S0950268817000309.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0950268817000309</ArticleId><ArticleId IdType="pmc">PMC9203317</ArticleId><ArticleId IdType="pubmed">28367766</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Q-Y, Wang Y, Bian L, Xu M, Liang Z. EV71 vaccine, a new tool to control outbreaks of hand, foot and mouth disease (HFMD). Expert Rev Vaccines. 2016;15(5):599&#x2013;606. doi:10.1586/14760584.2016.1138862.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14760584.2016.1138862</ArticleId><ArticleId IdType="pubmed">26732723</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Q, Ding J, Cao J, Huang Q, Hong C, Yang B. Epidemiological and etiological characteristics of hand, foot, and mouth disease in Wuhan, China from 2012 to 2013: outbreaks of coxsackieviruses A10. J Med Virol. 2015;87:954&#x2013;60. doi:10.1002/jmv.24151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.24151</ArticleId><ArticleId IdType="pubmed">25754274</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian H, Zhang Y, Shi Y, Li X, Sun Q, Liu L, Zhao D, Xu B. Epidemiological and aetiological characteristics of hand, foot, and mouth disease in Shijiazhuang City, Hebei province, China, 2009-2012. PLoS One. 2017;12:e0176604. doi:10.1371/journal.pone.0176604.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0176604</ArticleId><ArticleId IdType="pmc">PMC5423607</ArticleId><ArticleId IdType="pubmed">28486500</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen M, He S, Yan Q, Xu X, Wu W, Ge S, Zhang S, Chen M, Xia N. Severe hand, foot and mouth disease associated with Coxsackievirus A10 infections in Xiamen, China in 2015. J Clin Virol. 2017;93:20&#x2013;24. doi:10.1016/j.jcv.2017.05.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2017.05.011</ArticleId><ArticleId IdType="pubmed">28577423</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji H, Fan H, Lu PX, Zhang XF, Ai J, Shi C, Huo X, Bao C-J, Shan J, Jin Y, et al. Surveillance for severe hand, foot, and mouth disease from 2009 to 2015 in Jiangsu province: epidemiology, etiology, and disease burden. BMC Infect Dis. 2019;19:79. doi:10.1186/s12879-018-3659-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-018-3659-7</ArticleId><ArticleId IdType="pmc">PMC6341624</ArticleId><ArticleId IdType="pubmed">30669973</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed L, Muench H. A simple, method of estimating 50 percent end point. American Journal of Hygiene. 1938; 27, 493&#x2013;497</Citation></Reference><Reference><Citation>Lu QB, Zhang XA, Wo Y, Xu HM, Li XJ, Wang XJ, Ding S-J, Chen X-D, He C, Liu L-J, et al. Circulation of Coxsackievirus A10 and A6 in hand-foot-mouth disease in China, 2009-2011. PLoS One. 2012;7:e52073. doi:10.1371/journal.pone.0052073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0052073</ArticleId><ArticleId IdType="pmc">PMC3525556</ArticleId><ArticleId IdType="pubmed">23272213</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian H, Zhang Y, Sun Q, Zhu S, Li X, Pan Z, Xu W, Xu B. Prevalence of multiple enteroviruses associated with hand, foot, and mouth disease in Shijiazhuang City, Hebei province, China: outbreaks of coxsackieviruses a10 and b3. PLoS One. 2014;9(1):e84233. doi:10.1371/journal.pone.0084233.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0084233</ArticleId><ArticleId IdType="pmc">PMC3879295</ArticleId><ArticleId IdType="pubmed">24392117</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen AT, Tran TT, Hoang VM, Nghiem NM, Le NN, Le TT, Phan QT, Truong KH, Le NNT, Ho VL, et al. Development and evaluation of a non-ribosomal random PCR and next-generation sequencing based assay for detection and sequencing of hand, foot and mouth disease pathogens. Virol J. 2016;13(1):125. doi:10.1186/s12985-016-0580-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-016-0580-9</ArticleId><ArticleId IdType="pmc">PMC4937578</ArticleId><ArticleId IdType="pubmed">27388326</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoa-Tran TN, Nguyen AT, Dao ATH, Kataoka C, Ta HTT, Nguyen HTV, Takemura T, Nguyen TTT, Vu HM, Nguyen TTH, et al. Genetic characterization of VP1 of coxsackieviruses A2, A4, and A10 associated with hand, foot, and mouth disease in Vietnam in 2012-2017: endemic circulation and emergence of new HFMD-causing lineages. Arch Virol. 2020;165:823&#x2013;34. doi:10.1007/s00705-020-04536-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-020-04536-3</ArticleId><ArticleId IdType="pubmed">32008121</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji T, Guo Y, Huang W, Shi Y, Xu Y, Tong W, Yao W, Tan Z, Zeng H, Ma J, et al. The emerging sub-genotype C2 of CoxsackievirusA10 associated with hand, foot and mouth disease extensively circulating in mainland of China. Sci Rep. 2018;8(1):13357. doi:10.1038/s41598-018-31616-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-31616-x</ArticleId><ArticleId IdType="pmc">PMC6127217</ArticleId><ArticleId IdType="pubmed">30190558</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao W, Yue L, Yang T, Li H, Song X, Xie T, He X, Xie Z. A comparative study on biological characteristics of ten coxsackievirus A10 virus strains. Virology. 2021;555:1&#x2013;9. doi:10.1016/j.virol.2020.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2020.07.003</ArticleId><ArticleId IdType="pubmed">33418337</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Zhang C, Liu Q, Gong S, Geng L, Huang Z. A virus-like particle vaccine protects mice against coxsackievirus A10 lethal infection. Antiviral Res. 2018;152:124&#x2013;30. doi:10.1016/j.antiviral.2018.02.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2018.02.016</ArticleId><ArticleId IdType="pubmed">29470994</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen C, Liu Q, Zhou Y, Ku Z, Wang L, Lan K, Ye X, Huang Z. Inactivated coxsackievirus A10 experimental vaccines protect mice against lethal viral challenge. Vaccine. 2016;34:5005&#x2013;12. doi:10.1016/j.vaccine.2016.08.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2016.08.033</ArticleId><ArticleId IdType="pubmed">27562093</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z, Dong Z, Wang Q, Carr MJ, Li J, Liu T, Li D, Shi W. Characterization of an inactivated whole-virus bivalent vaccine that induces balanced protective immunity against coxsackievirus A6 and A10 in mice. Vaccine. 2018;36(46):7095&#x2013;104. doi:10.1016/j.vaccine.2018.09.069.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2018.09.069</ArticleId><ArticleId IdType="pubmed">30316529</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim H, In HJ, Lee JA, Sik Yoo J, Lee SW, Chung GT, Choi YK, Chung JK, Cho SJ, Lee J-W, et al. The immunogenicity and protection effect of an inactivated coxsackievirus A6, A10, and A16 vaccine against hand, foot, and mouth disease. Vaccine. 2018;36:3445&#x2013;52. doi:10.1016/j.vaccine.2018.05.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2018.05.005</ArticleId><ArticleId IdType="pubmed">29739716</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Dai W, Zhang C, Zhou Y, Xiong P, Wang S, Ye X, Liu Q, Zhou D, Huang Z, et al. A virus-like particle-based tetravalent vaccine for hand, foot, and mouth disease elicits broad and balanced protective immunity. Emerg Microbes Infect. 2018;7:94. doi:10.1038/s41426-018-0094-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41426-018-0094-1</ArticleId><ArticleId IdType="pmc">PMC5959873</ArticleId><ArticleId IdType="pubmed">29777102</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Q, Li N, Yu X, Yao X, Li F, Lu F, Zhuang H, Liang Z, Wang J. Antigenicity, animal protective effect and genetic characteristics of candidate vaccine strains of enterovirus 71. Arch Virol. 2012;157:37&#x2013;41. doi:10.1007/s00705-011-1136-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-011-1136-3</ArticleId><ArticleId IdType="pubmed">21984267</ArticleId></ArticleIdList></Reference><Reference><Citation>Gz MAOQY, Cs HAO, YU D, Gao F, Ch DONG, WQ AN, Gao Q, ZP XIE, Xl LI, ZL LIANG. Screening and preparation of candidate standard strain for determination of neutralizing antibody against enterovirus 71. Chin J Biologicals. 2012;25:725&#x2013;29.</Citation></Reference><Reference><Citation>Sun S, Gao F, Mao Q, Shao J, Jiang L, Liu D, Wang Y, Yao X, Wu X, Sun B, et al. Immunogenicity and protective efficacy of an EV71 virus-like particle vaccine against lethal challenge in newborn mice. Hum Vaccin Immunother. 2015;11(10):2406&#x2013;13. doi:10.1080/21645515.2015.1053675.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2015.1053675</ArticleId><ArticleId IdType="pmc">PMC4635907</ArticleId><ArticleId IdType="pubmed">26036916</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu CK, Chen CC, Chen CL, Wang JR, Liu CC, Yan JJ, Su IJ. Neutralizing antibody provided protection against enterovirus type 71 lethal challenge in neonatal mice. J Biomed Sci. 2000. Nov-Dec;7(6):523&#x2013;8. doi:10.1007/BF02253368</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF02253368</ArticleId><ArticleId IdType="pubmed">11060501</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizuta K, Aokia Y, Sutoa A, Ootani K, Katsushima N, Itagaki T, Ohmi A, Okamoto M, Nishimura H, Matsuzaki Y, et al. Cross-antigenicity among EV71 Ss from different genogroups isolated in Yamagata, Japan, between 1990 and 2007[J]. Vaccine. 2009;27:3153&#x2013;58. doi:10.1016/j.vaccine.2009.03.060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2009.03.060</ArticleId><ArticleId IdType="pubmed">19446185</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, An D, Liu W, Mao Q, Jin J, Xu L, Sun S, Jiang L, Li X, Shao J, et al. Analysis of cross-reactive neutralizing antibodies in human HFMD serum with an EV71 pseudovirus-based assay. PLoS One. 2014. 25;9(6):e100545. doi: 10.1371/journal.pone.0100545. eCollection 2014</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0100545</ArticleId><ArticleId IdType="pmc">PMC4070950</ArticleId><ArticleId IdType="pubmed">24964084</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu P, Yuan YD, Cui BP, Huo Y, Bian L, Chen L, Liu S, Wang C, Xu Y, Tedcastle A, et al. Cross-antigenicity between EV71 sub-genotypes: implications for vaccine efficacy. Viruses. 2021;13(5):720. doi:10.3390/v13050720.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13050720</ArticleId><ArticleId IdType="pmc">PMC8143144</ArticleId><ArticleId IdType="pubmed">33919184</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>